Compositions and methods including cell death inducers and procaspase activation

Patent metadata

Field	Value
Publication number	US-9522901-B2
Application number	US-201313893936-A
Country	US
Kind code	B2
Filing date	May 14, 2013
Priority date	May 26, 2005
Publication date	Dec 20, 2016
Grant date	Dec 20, 2016

Abstract

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

First claim

We claim:

1. The compound:

or a salt thereof.

2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The composition of claim 2 wherein the composition is an oral delivery formulation.

4. The composition of claim 3 wherein the oral delivery formulation comprises a sugar, a cellulose preparation, or a combination thereof.

5. The composition of claim 2 wherein the composition is a parenteral delivery formulation.

6. The composition of claim 5 wherein the parenteral delivery formulation is an aqueous suspension.

7. The compound:

or a salt thereof.

8. A composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

9. The composition of claim 8 wherein the composition is an oral delivery formulation.

10. The composition of claim 9 wherein the oral delivery formulation comprises a sugar, a cellulose preparation, or a combination thereof.

11. The composition of claim 8 wherein the composition is a parenteral delivery formulation.

12. The composition of claim 9 wherein the parenteral delivery formulation is an aqueous suspension.

13. The compound:

or a salt thereof.

14. A composition comprising a compound of claim 13 and a pharmaceutically acceptable carrier.

15. The composition of claim 14 wherein the composition is an oral delivery formulation.

16. The composition of claim 15 wherein the oral delivery formulation comprises a sugar, a cellulose preparation, or a combination thereof.

17. The composition of claim 13 wherein the composition is a parenteral delivery formulation.

18. The composition of claim 17 wherein the parenteral delivery formulation is an aqueous suspension.

19. The compound:

or a salt thereof.

20. A composition comprising a compound of claim 19 and a pharmaceutically acceptable carrier.

Assignees

• Univ Illinois

Inventors

• Hergenrother Paul J
• Putt Karson S
• Peterson Quinn P
• Fako Valerie

Classifications

• A61K31/495 Primary

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title

• C07D211/62

  attached in position 4 · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• C07D401/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D295/13

  to an acyclic saturated chain · CPC title